Insmed
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
700 Us Highway 202/206, Bridgewater, New...Phone Number
(908) 977-9900Website
www.insmed.comRevenue
$1.1 BillionStock Symbol
INSMIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
2
2
1
1
1
About Insmed
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.Explore more
Insmed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Insmed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Insmed has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Insmed is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Insmed had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Insmed
Insmed, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Insmed recently announced quarterly report
Product Launch: Get notified when Insmed launches new products
Check if Insmed has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Insmed as Masked Content
Find 3 more new buyers
Compare Similar Companies to Insmed
Compare insights from companies similar to Insmed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Insmed is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Insmed is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Insmed.
Insmed financials insights
Gather financial insights about Insmed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Debt
$775M
Insmed Tech Stack
A closer look at the technologies used by Insmed
See more technologies
Most Recent Scoops
Project
Insmed has announced that the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) has announced its intention to collaborate with Insmed to evaluate brensocatib's 25 mg dose in a three-year open-label study of up to 3,000 patients with bronchiectasis across six European countries, with the goal of assessing the potential for long-term disease modification and the effectiveness of earlier use in slowing disease progression.
Medical Research, Pharmaceuticals
Earnings
Insmed has updated its peak sales estimate for TPIP to greater than $6 billion, up from its previous projection of greater than $2 billion, assuming clinical and regulatory success across all four indications PH-ILD, PAH, PPF, and IPF and that TPIP's profile continues to demonstrate meaningful differentiation versus other prostanoids with comparable efficacy to sotatercept and a favorable tolerability profile.
Sales
Earnings
Insmed has reported that the combined peak sales estimates for ARIKAYCE now exceed $14 billion, up 75% from the company's previous combined peak sales estimate of greater than $8 billion for these three products.
Pharmaceuticals
Project
Insmed has announced that TPIP is emerging as a potentially differentiated asset across four large indications PH-ILD, PAH, PPF, and IPF with data from an ongoing open-label extension study in PAH patients supporting the belief that TPIP has the potential to become the prostanoid of choice.
Pharmaceuticals
Open Position
Insmed News & Media
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of...Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
—New Data Explore Efficacy and Safety of BRINSUPRI ® (brensocatib) in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of Nontuberculous Mycobacterial (NTM) Lung Disease— —New Research Examines Treprostinil Palmitil Inhalation Powder (TPIP) via COMPERA 2.0 Risk...Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business
On August 6, Insmed (NASDAQ:INSM) reported second-quarter results that mark a turning point for a company long defined by red ink. Total revenue hit $425.5 million, up 296% from the same quarter of 2025, and the net loss shrank from $321.7 million a year ago to just $13.2 million. The numbers tell the story of […]Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Insmed
Sign Up For FreeTo access detailed company insights
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients... Read More
